Hem › Ulcerös kolit › New York › New York City
Kliniska studier för Ulcerös kolit i New York City, NY
23 studier för Ulcerös kolit söker deltagare vid platser i och runt New York City (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
RekryterarFas 2
- New York Gastroenterology Associates - Upper East Side /ID# 281767, New York
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
RekryterarFas 1
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- NYP/Weill Cornell Medical Center, New York
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
RekryterarFas 3
- New York Gastroenterology Associates ( Site 0253), New York
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
RekryterarFas 2
- Pioneer Clinical Research NY, New York
A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
RekryterarFas 4
- New York Gastroenterology Associates, New York
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
RekryterarFas 2
- Site 037, New York
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
RekryterarFas 3
- Inflammatory Bowel Disease Center at NYU Langone, New York
- Icahn School of Medicine at Mount Sinai, New York
- Weill Cornell Medical College, New York
- och 2 fler
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
RekryterarFas 2/3
- Columbia University Medical Center, New York
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
RekryterarFas 3
- Icahn School of Medicine at Mount Sinai, New York
- New York Gastroenterology Associates, New York
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
RekryterarFas 3
- Icahn School of Medicine at Mount Sinai, New York
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
RekryterarFas 4
- NYU Langone Health, New York
- Weill Cornell Medical College- New York Presbyterian Hospital, New York
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
RekryterarFas 3
- Weill Cornell Medicine - NewYork-Presbyterian Hospital - Site Number: 8400040, New York
- New York Gastroenterology Associates - Site Number: 8400009, New York
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
RekryterarFas 3
- New York Gastroenterology Associates, New York
A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis
RekryterarFas 2
- Fink Children's Ambulatory Care Center, New York
- Kimmel Pavilion - NYU Langone, New York
- NYU Grossman School of Medicine, New York
- och 4 fler
A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis
RekryterarFas 2
- Columbia University Medical Center, New York
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
RekryterarFas 3
- Manhattan Clinical Research, LLC - Site Number: 8400069, New York
- NYU Langone Health - Site Number: 8400091, New York
- Weill Cornell Medical College - NewYork-Presbyterian Hospital - Site Number: 8400040, New York
- och 2 fler
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
Rekryterar
- NYU Langone Health, New York
- Cornell University, New York
BOOM-IBD2 Pivotal Clinical Trial
Rekryterar
- Columbia University Irving Medical Center/New York Presbyterian Hospital, New York
Zymfentra (Infliximab-dyyb) REal World Cohort STudy
RekryterarObservationsstudie
- New York University, New York
An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis
RekryterarObservationsstudie
- NYU Langone Health, New York
- Lenox Hill Hospital, Northwell Health, New York
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
RekryterarFas 3
- New York Presbyterian Hospital, New York
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
RekryterarFas 2
- Mirador Therapeutics Selected Site, New York
Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention
RekryterarObservationsstudie
- New York University, New York
Ulcerös kolit-studier i andra städer
- Orlando, FL22 studier
- Miami, FL21 studier
- Houston, TX17 studier
- San Antonio, TX16 studier
- Tyler, TX15 studier
- Tacoma, WA15 studier
- Chicago, IL15 studier
- San Diego, CA15 studier
- Colorado Springs, CO14 studier
- Los Angeles, CA13 studier
- St. Louis, MO13 studier
- Washington, DC12 studier
Andra studier i New York City
- Bröstcancer136 studier
- Icke-småcellig lungcancer121 studier
- Cancer (alla typer)109 studier
- Prostatacancer103 studier
- Metastaserande cancer93 studier
- Kolorektal cancer78 studier
- Äggstockscancer69 studier
- Lungcancer60 studier
- Multipelt myelom60 studier
- Bukspottkörtelcancer60 studier
- Endometriecancer52 studier
- Akut myeloid leukemi51 studier
Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.